相关临床试验
388
38 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1824
进行中（未招募）
23
5.9%
已完成
196
50.5%
Enrolling By Invitation
4
1.0%
尚未招募
11
2.8%
招募中
63
16.2%
暂停
7
1.8%
终止
31
8.0%
Unknown
38
9.8%
撤回
15
3.9%
暂无批准数据
- A woman in her 40s in Rwanda with no smoking history presented with worsening chest pain and a CT-detected lung mass highly suggestive of malignancy, but PET-CT was unavailable locally, leaving diagnosis and staging unresolved. - The case illustrates how limited access to advanced imaging in low-resource settings can delay diagnosis, force empiric management, and risk missed opportunities for curative intervention. - PET imaging can identify occult metastatic disease, distinguish localized from advanced disease, and guide biopsy, but access remains deeply unequal across low- and middle-income countries and even within high-income nations. - The author calls for regional diagnostic hubs, public-private partnerships, structured referral pathways, and context-specific guidelines to strengthen equitable access to staging tools.
- An interim analysis of the first-in-human Phase 1 trial of LASSARAB, an inactivated rabies-vectored Lassa fever vaccine, demonstrated 100% seroconversion against both Lassa virus and rabies virus by day 61 in healthy adults. - The vaccine was well tolerated across all dose groups, with no serious adverse events or grade ≥3 reactions; solicited symptoms were predominantly mild and self-limited. - All LASSARAB recipients achieved rabies-neutralizing antibody titers exceeding the WHO correlate of protection (≥0.5 IU/ml), matching responses seen with licensed rabies vaccines. - The study, published in Nature Medicine and conducted at the University of Maryland, supports advancing LASSARAB to larger trials in endemic settings, offering potential dual protection against two priority pathogens.
- Aprea Therapeutics has appointed industry veteran Eugene Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept demonstrated in its ongoing Phase 1 study of WEE1 inhibitor APR-1051. - Dr. Kennedy brings over 20 years of oncology clinical development experience and has previously served as Chief Medical Officer at multiple biotechnology companies including Carisma Therapeutics and Galera Therapeutics. - The appointment strengthens Aprea's clinical leadership as the company advances dose escalation and refines patient selection for its DNA damage response program targeting multiple solid tumor types.
- The Portal extension trial showed that 50% of patients with wet age-related macular degeneration maintained 20/40 vision for up to 7 years using the Port Delivery System with ranibizumab. - Continuous drug delivery via the implantable device resulted in minimal vision loss of only 2-7 letters over 7 years, significantly better than traditional injection regimens. - The system maintained 95% durability across refill-exchange intervals with reduced treatment burden, requiring refills only every 24 weeks. - Long-term anatomic control was sustained throughout the study period, with endophthalmitis rates of 3% that decreased after surgical technique improvements were implemented.
- Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial. - HMBD-002 is a monoclonal antibody targeting the immune checkpoint regulator VISTA that has completed phase I testing with favorable safety and tolerability data. - The company plans to commence recruitment for the phase II trial of HMBD-002 in calendar year 2026, marking a critical advancement in the oncology program. - Dr Kennedy brings over a decade of immuno-oncology experience from roles at Johns Hopkins and Carisma Therapeutics, while Dubljevic will focus on manufacturing and regulatory compliance.
- The C-MIC II randomized controlled trial demonstrated that microcurrent therapy significantly improved left ventricular ejection fraction by 5.1% compared to controls in heart failure patients with reduced ejection fraction. - Patients receiving the implantable Cardio-Microcurrent device showed superior functional improvements, with 84% achieving at least one NYHA class improvement versus 15% in the control group. - The therapy was well-tolerated with no device-related serious adverse events, establishing a new bioelectronic treatment paradigm for non-ischemic cardiomyopathy patients who remain symptomatic despite optimal medical therapy.
- Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care. - Dr. Pierluigi Porcu emphasizes that effective CLL management requires understanding disease risk, patient comorbidities, and practice environment constraints including payer considerations. - Despite its importance, value-based care adoption remains insufficient in oncology, with challenges in defining and measuring value across patient outcomes, quality of life, and treatment costs.
- The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients. - Developed by researchers at Thomas Jefferson University, LASSARAB demonstrated complete protection in nonhuman primates exposed to lethal doses of Lassa virus, representing a significant advancement in addressing this West African endemic disease. - The trial will enroll 55 healthy adults to evaluate three different concentrations of the vaccine, which uniquely combines protection against both Lassa fever and rabies through a modified inactivated rabies vaccine platform.
- Researchers at Sidney Kimmel Cancer Center are developing an innovative anti-MDM2 PROTAC therapy that targets p73 activation to induce cancer cell death in p53-mutated tumors. - The experimental treatment works by degrading MDM2 proteins, triggering cellular stress that activates p73, which shares transcriptional targets with p53 and can promote apoptosis. - The research team, led by Dr. Christine M. Eischen, is currently optimizing the MDM2 PROTAC compound before advancing to clinical trials with cancer patients.
• Xaluritamig, a STEAP1-targeted T-cell engager, demonstrates significant clinical activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. • The optimized dosing schedule of Xaluritamig, involving step dosing to 1.5 mg every other week, improves tolerability and reduces musculoskeletal-related adverse events. • Clinical trials show impressive response rates, including in patients with liver metastases, with durable outcomes comparable to existing treatments like the VISION trial. • A phase 3 trial is planned to compare Xaluritamig to standard therapies, with potential to change clinical practice in late-stage prostate cancer management.
